You are here » Home » Companies » Company Overview » Brawn Biotech Ltd

Brawn Biotech Ltd.

BSE: 530207 Sector: Others
NSE: N.A. ISIN Code: INE899B01015
BSE 12:30 | 16 Feb 62.00 0.70
(1.14%)
OPEN

64.35

HIGH

64.35

LOW

61.30

NSE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 64.35
PREVIOUS CLOSE 61.30
VOLUME 790
52-Week high 95.60
52-Week low 46.80
P/E 15.12
Mkt Cap.(Rs cr) 19
Buy Price 62.00
Buy Qty 100.00
Sell Price 64.10
Sell Qty 465.00
OPEN 64.35
CLOSE 61.30
VOLUME 790
52-Week high 95.60
52-Week low 46.80
P/E 15.12
Mkt Cap.(Rs cr) 19
Buy Price 62.00
Buy Qty 100.00
Sell Price 64.10
Sell Qty 465.00

Brawn Biotech Ltd. (BRAWNBIOTECH) - Chairman Speech

Company chairman speech

Dear Shareholders

I thank all of you as you have rested your faith in our potential.

At Brawn our business objectives have always been aligned with the demand and need ofcustomers. We believe in providing best and competitive products in the market. Ourgrowth over the years has been characterized by our ability to innovation and execution.We not only believe in planning preparing and performing but with this we believe inproper execution of plans. Our mission is to seek global market leadership and to strivefor excellence in customer service quality and R & D.

Our Company is engaged in marketing of medicinal and allied health products and has awell- defined marketing network with a staff of over 180 covering major hospitals andinstitutions in India. Our entry into the export market in 2013- 14 resulted in quantumjump in revenues and growth.

Our success in steering the Company through the challenging times has led us to step updividend during financial year 2015-16 and will be announcing higher dividend in furtheryears. This is an expression of our confidence in the health of the Company and itsprospects and reflects our commitment to ensuring shareholders participation in oursuccess. Planning and preparedness across every aspect of our business have borne fruit inthe performance outcomes of Financial Year 2017. We worked and reworked patiently inimproving quality across the industry. We believe that the only way to stay ahead or tocompete in the global market is investing in innovation and people. We are grateful to allour employees for their dedication passion and smart work which helped us to excel and toreach where we are.

INCOME IN 2016-17

In FY 2016 we concurrently are expanding operating and net profit margins due to ourcontinuous focus on improvement:

Snapshot

Year 2016-17 2015-16 GROWTH
Net Sales 5960.58 4562.24 30.65%
EBIDTA 182.13 140.07 30.03%
EBIDTA Margin 2.98% 2.99% -0.01%
NET PROFIT 139.24 94.97 46.61%
NET PROFIT MARGIN (%) 2.28% 2.03% 0.25%

Our Company operates business with highest ethical standards and remain committedtowards achieving profitable growth. The total income of the Company improves in everyyear.

With increase in total income the revenue increased by 29.14% over previous year whilethe EBITDA margin widened to Rs. 182.13 lacs as compared to Rs. 140.07 Lacs in 2015-16.The earning per share grew by 46.37% in 2016-17.

We monitor operating margins and manage costs to ensure the business is cost effective.Also we are ensuring accuracy of financial reporting with effective Internal Controls.

OUR WAY FORWARD

With our technical excellence and expertise in quality assurance the Company isbuilding leadership position in the business. Our aim is to build a tomorrow that all areproud of. We will execute the strategies with the same commitment and passion that we areknown for. Looking forward we expect to overcome short- term challenges and deliverlong-term sustainable growth.

Lastly I thank every member of the Company for their continued support to the Companyand for helping us perform year after year and believe that an interesting and successfulfuture lies ahead of us.

Regards

Sd/-

Brij Raj Gupta

Chairman & Managing Director